
Join to view full profile
55 Lake Ave N# HematoloWorcester, MA 01655
Phone+1 508-334-7098
Fax+1 508-856-6715
Dr. Liebmann is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of WashingtonResidency, Internal Medicine, 1983 - 1986
University of California San Francisco School of MedicineClass of 1983
National Institutes of Health Clinical CenterFellowship, Medical Oncology
Certifications & Licensure
MA State Medical License 2008 - 2027
NM State Medical License 1994 - 2010
MD State Medical License 1989 - 1994
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Allscripts Enterprise E HR Modular, Allscripts, 2012-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification Meaningful Use Advisor, MedCPU Inc., 2012-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Allscripts Enterprise EHR, Allscripts, 2012-2014, 2016-2017
Clinical Trials
Publications & Presentations
PubMed
- 8 citationsPhysiological measurements corroborate symptomatic improvement after therapeutic leukapheresis in a pregnant woman with chronic myelogenous leukemia.Pallavi Galera, Stefanie Haynes, Paula Sulmasy, Jeffrey A. Bailey, Mindy Greene
Journal of Clinical Apheresis. 2016-08-01 - 2 citationsThe Diagnostic Utility of Tumor Markers: A Teachable MomentJustin K. Lui, Adedotun Ogunsua, Steven C. Hatch, James Liebmann, Gail Scully
The American Journal of Medicine. 2015-05-01 - 15 citationsPixantrone dimaleate in combination with fludarabine, dexamethasone, and rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: phase 1 study...Tomasz P. Srokowski, James Liebmann, Manuel Modiano, Gary I. Cohen, Barbara Pro
Cancer. 2011-11-15
Press Mentions
ODAC Votes Against Panobinostat in Multiple MyelomaFebruary 10th, 2016
5K Raises $279,000 to Advance Cancer Services, ResourcesJuly 10th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









